Coronary artery disease in adults with tetralogy of Fallot.


Journal

Congenital heart disease
ISSN: 1747-0803
Titre abrégé: Congenit Heart Dis
Pays: United States
ID NLM: 101256510

Informations de publication

Date de publication:
May 2019
Historique:
received: 07 03 2019
revised: 06 04 2019
accepted: 22 04 2019
pubmed: 15 5 2019
medline: 3 1 2020
entrez: 15 5 2019
Statut: ppublish

Résumé

There are limited data about outcomes of coronary artery disease (CAD) in adults with repaired tetralogy of Fallot (TOF). The purpose of this study was to describe the prevalence and treatment of CAD in adults with TOF, and the impact of CAD on long-term survival. Retrospective review of MACHD database for adults with repaired TOF who underwent aortic root/selective coronary angiogram, 1990-2017. Patients were categorized into three groups: (1) No CAD defined as normal coronary angiogram; (2) Mild CAD defined as ≤50% stenosis in all vessels; and, (3) Significant CAD defined as >50% stenosis in any vessel. We identified 105 (23%) of 465 TOF patients that had angiograms; mean age 47 ± 12 years. The prevalence of mild CAD and significant CAD was 19% (20 patients) and 15% (16 patients), respectively. Of these 16 patient with significant CAD, 9 (56%), 3 (19%), and 4 (24%) patients received guideline directed medical therapy, percutaneous coronary intervention, and coronary artery bypass grafting, respectively. Significant CAD was an independent risk factor for mortality (HR: 2.03, 95% CI 1.64-4.22, P = .022) after adjustment for differences in age, and prevalence of atrial fibrillation and renal dysfunction. Based on a review of a selected cohort of 105 TOF patients, the prevalence of mild CAD and significant CAD was 19% and 15%, respectively. Significant CAD was an independent risk factor for mortality. There is need for more research to determine optimal noninvasive diagnostic strategies and optimal patient selections and methods for revascularization.

Sections du résumé

BACKGROUND BACKGROUND
There are limited data about outcomes of coronary artery disease (CAD) in adults with repaired tetralogy of Fallot (TOF). The purpose of this study was to describe the prevalence and treatment of CAD in adults with TOF, and the impact of CAD on long-term survival.
METHODS METHODS
Retrospective review of MACHD database for adults with repaired TOF who underwent aortic root/selective coronary angiogram, 1990-2017. Patients were categorized into three groups: (1) No CAD defined as normal coronary angiogram; (2) Mild CAD defined as ≤50% stenosis in all vessels; and, (3) Significant CAD defined as >50% stenosis in any vessel.
RESULTS RESULTS
We identified 105 (23%) of 465 TOF patients that had angiograms; mean age 47 ± 12 years. The prevalence of mild CAD and significant CAD was 19% (20 patients) and 15% (16 patients), respectively. Of these 16 patient with significant CAD, 9 (56%), 3 (19%), and 4 (24%) patients received guideline directed medical therapy, percutaneous coronary intervention, and coronary artery bypass grafting, respectively. Significant CAD was an independent risk factor for mortality (HR: 2.03, 95% CI 1.64-4.22, P = .022) after adjustment for differences in age, and prevalence of atrial fibrillation and renal dysfunction.
CONCLUSIONS CONCLUSIONS
Based on a review of a selected cohort of 105 TOF patients, the prevalence of mild CAD and significant CAD was 19% and 15%, respectively. Significant CAD was an independent risk factor for mortality. There is need for more research to determine optimal noninvasive diagnostic strategies and optimal patient selections and methods for revascularization.

Identifiants

pubmed: 31083772
doi: 10.1111/chd.12782
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

491-497

Subventions

Organisme : National Heart, Lung, and Blood Institute
ID : K23 HL141448-01

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Alexander C Egbe (AC)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.

Sindhura Ananthaneni (S)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.

Raja Jadav (R)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.

Srikanth Kothapalli (S)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.

Charanjit S Rihal (CS)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.

Muhammad Masood (M)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.

Mounika Angirekula (M)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.

Maria Najam (M)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.

Numra Bajwa (N)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.

Karim Tarek (K)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.

Jessey Matthew (J)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.

Heidi M Connolly (HM)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH